Summit Therapeutics Inc (NASDAQ:SMMT) currently has a daily average trading volume of 5.05M but it saw 2279244 shares traded in last market. With a market cap of 15.55B USD, the company’s current market price of $21.10 came rising about 1.01 while comparing to the previous closing price of $20.89. In past 52 weeks, the stock remained buoying in the range of price level as high as $33.89 and as low as $1.64. In the recent trading on the day, stock has struck highest price mark of $20.26 while lowest mark touched by it was $21.6806.
Taking a look at 20-day trading activity of Summit Therapeutics Inc (SMMT) gives us an average price of $20.64, while its current price level is -37.74% below from 52-week high level whereas it is 1186.59% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $20.55 while that of 200 days or SMA-200 reads an average of $9.96. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.44% during that period while stretching the period over a month that increases to 7.81%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.38 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the JMP Securities which initiated the stock as “Mkt Outperform” in its note to investors issued on November 04, 2024, recommending a price target of $32 for it. Citigroup downgraded its recommendation for the stock as a “Neutral” from “Buy” on September 27, 2024 while assigning a price target range of $19-$23. H.C. Wainwright also issued its recommendations for the stock as it initiated the price target for the stock is $16.
Over the week, SMMT’s stock price is moving 13.50% up while it is 11.64% when we observe its performance for the past one month. Year-to-date it is 708.43% up and over the past year, the stock is showing an upside performance of 1001.83%.
Currently, Summit Therapeutics Inc’s total number of outstanding shares is 701.66M. Company’s return on investment (ROI) stands at -44.49% and return on equity (ROE) at -73.22%. Stock’s beta reads -0.89. Stock has a price to book (P/B) ratio of 35.51. Its return on asset (ROA) is -54.54% on average.
